Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Urology ; 140: 155-158, 2020 06.
Article in English | MEDLINE | ID: mdl-32199873

ABSTRACT

Bilateral testicular tumors are very rare in pediatric patients and only a few case reports have been reported. These patients have a high risk of sterility due to bilateral orchiectomy and subsequent gonadotoxic treatments. Therefore, if possible, testis-sparing surgery should be performed in patients with benign masses and testicular tissue preservation may be recommended in order to maintain fertility in later life. We present a 23 months old boy with synchronous bilateral testicular tumor managed with unilateral orchiectomy and testis-sparing surgery and testicular tissue cryopreservation performed to the controlateral side. We also review the literature on bilateral testis tumors in children.


Subject(s)
Cryopreservation/methods , Neoplasms, Germ Cell and Embryonal , Neoplasms, Multiple Primary , Orchiectomy/methods , Organ Sparing Treatments/methods , Teratoma , Testicular Neoplasms , Testis , Humans , Infant , Male , Neoplasms, Germ Cell and Embryonal/blood , Neoplasms, Germ Cell and Embryonal/pathology , Neoplasms, Germ Cell and Embryonal/surgery , Neoplasms, Multiple Primary/blood , Neoplasms, Multiple Primary/pathology , Neoplasms, Multiple Primary/surgery , Teratoma/blood , Teratoma/pathology , Teratoma/surgery , Testicular Neoplasms/blood , Testicular Neoplasms/pathology , Testicular Neoplasms/surgery , Testis/diagnostic imaging , Testis/pathology , Testis/surgery , Tissue Preservation/methods , Treatment Outcome , Ultrasonography/methods , alpha-Fetoproteins/analysis
2.
J Pediatr Hematol Oncol ; 32(4): e155-7, 2010 May.
Article in English | MEDLINE | ID: mdl-20445411

ABSTRACT

SUMMARY: Desmoplastic small round-cell tumor (DSRCT) is a rare and aggressive tumor that usually affects young males. Abdominal or pelvic disease is generally present in patients with DSRCT. Despite multimodality treatment, it still remains highly aggressive and has poor prognosis. We report a 16-year-old male with DSRCT in the mandible, an unusual site of the disease, treated with chemo-radiotherapy but recurred in an unexpected site 5 months after the completion of treatment.


Subject(s)
Bone Neoplasms/secondary , Carcinoma, Small Cell/secondary , Foot Diseases/etiology , Mandibular Neoplasms/pathology , Adolescent , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Neoplasms/therapy , Carcinoma, Small Cell/drug therapy , Carcinoma, Small Cell/radiotherapy , Combined Modality Therapy , Fatal Outcome , Humans , Lymphatic Metastasis , Magnetic Resonance Imaging , Male , Mandibular Neoplasms/drug therapy , Mandibular Neoplasms/radiotherapy , Radiotherapy Dosage
3.
Pediatr Hematol Oncol ; 25(7): 621-9, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18850474

ABSTRACT

Matrix metalloproteinases (MMP) are enzymes involved in the reconfiguration of the microenvironment by means of degrading the extracellular matrix and have more than 20 subgroups containing zinc. Proteins that serve as the inhibitors of these enzymes are called tissue inhibitors of matrix metalloproteinase (TIMP). These enzymes have been shown to be active in a wide range of processes, from wound recovery to fetus development, heart diseases, and spread of malignant diseases. The aim of this study was to investigate whether there is a relationship between the type, stage, and prognosis of childhood lymphoma subjects and matrix metalloproteinase type-9 (MMP-9) and its inhibitor, tissue inhibitor of matrix metalloproteinase type-1 (TIMP-1). Paraffin blocks of childhood patients diagnosed with non-Hodgkin lymphoma (n = 23), Hodgkin lymphoma (n = 14), or reactive lymphadenopathy (n = 12) were retrospectively immunohistochemically stained with MMP-9 and TIMP-1 stains and whether there was a relationship between the degree of staining and the type, tumor stage, and prognosis of the disease was investigated. Moderate and high degrees of MMP-9 staining were detected in 94.6% of the lymphoma patient tissues and a slight TIMP-1 staining was detected in 21.6% of the lymphoma patient tissues. No relationship was observed between the degree of these staining patterns and the type, tumor stage, and prognosis of the disease. This study indicates that the equilibrium between MMP-9 and TIMP-1 is important in lymphomas in addition to all the physiological and pathologic events although MMP-9 and the TIMP-1 staining patterns are not related to the tumor stage, prognosis, and type of the disease. Larger series of patients are needed to determine the prognostic value of MMP-9 and TIMP-1 in childhood lymphoma.


Subject(s)
Hodgkin Disease/metabolism , Lymphoma, Non-Hodgkin/metabolism , Matrix Metalloproteinase 9/metabolism , Tissue Inhibitor of Metalloproteinase-1/metabolism , Adolescent , Child , Child, Preschool , Female , Hodgkin Disease/diagnosis , Hodgkin Disease/pathology , Humans , Infant , Lymphocytes/cytology , Lymphocytes/metabolism , Lymphoma, Non-Hodgkin/diagnosis , Lymphoma, Non-Hodgkin/pathology , Male , Retrospective Studies
4.
Leuk Lymphoma ; 46(8): 1177-81, 2005 Aug.
Article in English | MEDLINE | ID: mdl-16085559

ABSTRACT

Ca 125 is a tumor marker for the diagnosis and monitoring of ovarian carcinoma. We investigated serum Ca 125 levels in 44 children with leukemia and 59 children with lymphoma at initial presentation and 4 weeks after chemotherapy. Serum Ca 125 levels were measured chemilumimetrically with a sandwich enzyme-linked immunosorbent assay. The incidence of elevated serum Ca 125 levels was significantly higher in children with leukemia (14 children) and lymphoma (26 children) than in the healthy children (2 children). In the patients with non-Hodgkin's lymphoma (NHL) who had abdominal involvement and/or serous membrane involvement (ascides, pleural, pericardial effusion) at presentation, serum Ca 125 levels were significantly higher than in the patients without abdominal and/or serosal involvement. Serum Ca 125 levels were impressively increased in the patients with Burkitt's lymphoma (BL) in whom abdominal and/or serous membrane involvement were observed more frequently than the other types of lymphoma. The increased serum Ca 125 levels in the patients returned to normal 4 weeks after chemotherapy when they achieved complete remission. In conclusion, serum Ca 125 seems to be a good indicator for serous membrane involvement and it seems to be a promising tumor marker in the assessment of therapeutic response in children with leukemia and NHL.


Subject(s)
Burkitt Lymphoma/blood , CA-125 Antigen/blood , Hodgkin Disease/blood , Leukemia, Myeloid, Acute/blood , Lymphoma, Non-Hodgkin/blood , Precursor Cell Lymphoblastic Leukemia-Lymphoma/blood , Burkitt Lymphoma/therapy , Child , Enzyme-Linked Immunosorbent Assay/methods , Female , Hodgkin Disease/therapy , Humans , Leukemia, Myeloid, Acute/therapy , Lymphoma, Non-Hodgkin/therapy , Male , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Predictive Value of Tests , Remission Induction/methods
5.
Pediatr Hematol Oncol ; 21(1): 77-83, 2004.
Article in English | MEDLINE | ID: mdl-14660309

ABSTRACT

The purpose of this study is to investigate the hemostatic side effects of HDMTX. Between 2001 and 2002, 20 children with acute lymphoblastic leukemia at the Dr. Sami Ulus Children's Hospital, Department of Pediatric Hematology and Oncology, treated according to the St. Jude ALL XIII protocol were eligible to this study. Methotrexate at a dose of 2 g/m(2) was infused over 24 hours. Coagulation screening studies included prothrombin time (PT), APTT, fibrinogen, fibrin degradation product (D-Dimer), factor II, factor V, factor VII, factor VIII, factor IX, factor X, PC, PS, AT-III determinations before HDMTX therapy (PreT), 1 day after (PostT(1D)), and 1 week after (PostT(1W)) the end of the HDMTX infusion. We found that PT and APTT were prolonged, PC, PS, and AT-III levels were decreased with a slight increase in D-Dimer 1 day after the administration of HDMTX and all of them returned to the normal levels by 7 days. In addition we found that FVII, FIX, FX were significantly decreased 1 day after therapy and normalised by 7 days.


Subject(s)
Methotrexate/adverse effects , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Adolescent , Blood Coagulation Factors/drug effects , Child , Child, Preschool , Dose-Response Relationship, Drug , Female , Hemostasis/drug effects , Humans , Male , Methotrexate/administration & dosage , Precursor Cell Lymphoblastic Leukemia-Lymphoma/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...